TEM:NSD-Tempus AI, Inc. Class A Common Stock (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 40.45

Change

0.00 (0.00)%

Market Cap

USD 9.00B

Volume

4.56M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-20 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
GEHC GE HealthCare Technologies Inc..

N/A

USD 28.76B
HQY HealthEquity Inc

N/A

USD 7.52B
WAY Waystar Holding Corp. Common S..

N/A

USD 4.47B
BTSG BrightSpring Health Services, ..

N/A

USD 3.00B
PRVA Privia Health Group Inc

N/A

USD 2.92B
PINC Premier Inc

N/A

USD 1.93B
SDGR Schrodinger Inc

N/A

USD 1.79B
GDRX Goodrx Holdings Inc

N/A

USD 1.73B
CERT Certara Inc

N/A

USD 1.60B
OMCL Omnicell Inc

N/A

USD 1.53B

ETFs Containing TEM

ARCG:LSE ARK Genomic Revolution UC.. 9.09 % 0.00 %

N/A

USD 8.76M
ARKG:LSE ARK Genomic Revolution UC.. 8.27 % 0.00 %

N/A

USD 8.76M
ARKG ARK Genomic Revolution ET.. 6.97 % 0.75 %

N/A

USD 0.94B
REMX VanEck Rare Earth/Strateg.. 6.95 % 0.59 %

N/A

N/A
XME SPDR® S&P Metals and Min.. 4.97 % 0.35 %

N/A

N/A
PSCM Invesco S&P SmallCap Mate.. 4.94 % 0.29 %

N/A

USD 0.01B
ARCK:LSE ARK Innovation UCITS ETF .. 4.69 % 0.00 %

N/A

USD 0.04B
ARKK ARK Innovation ETF 4.55 % 0.75 %

N/A

USD 4.88B
ARKK:LSE ARK Innovation UCITS ETF .. 4.16 % 0.00 %

N/A

USD 0.04B
AIAG:LSE L&G Artificial Intelligen.. 2.24 % 0.00 %

N/A

USD 0.84B
AIAI:LSE L&G Artificial Intelligen.. 2.24 % 0.00 %

N/A

USD 0.82B
DOCT:SW L&G Healthcare Breakthrou.. 1.92 % 0.00 %

N/A

USD 0.06B
SPXZ 1.50 % 0.00 %

N/A

N/A
PBW Invesco WilderHill Clean .. 0.00 % 0.70 %

N/A

N/A
PYZ Invesco DWA Basic Materia.. 0.00 % 0.60 %

N/A

USD 0.05B
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

N/A

USD 0.04B
THNQ Robo Global® Artificial .. 0.00 % 0.00 %

N/A

USD 0.15B

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.82% 85% B 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.82% 85% B 92% A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 9.00B 98% N/A 93% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.